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Squamous cell carcinoma of the oesophagus (SCCE) is the sixth
most frequent cancer worldwide (Pisani et al, 1999). Incidence
rates vary greatly between different parts of the world (for review,
see Muñoz and Day, 1996). Areas of extremely high incidence are
found in northern Iran (Turkoman plain) and central China (Henan
province and Shanxi), where incidence rates (ASR) of over
100/100 000/year have been reported in both men and women.
Other, less clearly defined high incidence areas are found in parts
of South America and in south and east Africa (Muñoz and Day,
1996). In Europe and in the United States, the overall incidence
does not exceed 10/100 000/year in men and 2/100 000/year in
women. However, in several areas, higher incidence rates have
been observed exclusively in men (up to 30/100 000/year). These
areas include the north-west of France (Normandy and Brittany)
and the north-east of Italy (Veneto) (Launoy et al, 1994; Parkin 
et al, 1997; Zambon et al, 2000). In industrialised countries, it is
estimated that 90% of SCCE is attributable to tobacco and alcohol
consumption, with a multiplicative effect in individuals exposed to
both factors (Tuyns, 1987). In the rest of the world, a variety of
cultural and dietary habits have been incriminated. These include
the consumption of scalding hot beverages and a deficiency in
fresh fruits and vegetables (in most areas of very high incidence), a
high dietary nitrosamine content (in China and south-east Asia)
and the oral consumption of opium by-products (in Northern Iran)
(Muñoz and Day, 1996). 
Mutation of the TP53 gene is the most frequent genetic alter-
ation described to date in SCCE, occurring in 35% to 70% of
cancers, depending on the study and on the geographical origin of
the tumours (Tanière et al, 2000b). Mutations are thought to occur
at an early stage and have been observed in dysplasia, in normal
mucosa adjacent to cancer lesions, and in oesophagitis in indi-
viduals from Normandy (Mandard et al, 2000). By comparing
tumours from China, Thailand and western Europe, we have
recently shown that the distribution and the nature of TP53 muta-
tions varied according to their geographic origin. This raises the
possibility that the mutation pattern may provide clues on the
nature of the specific mutagens involved in oesophageal carcino-
genesis (Tanière et al, 2000b). 
The data available on TP53 mutations in tumours from Western
Europe are essentially limited to areas of high incidence of
Normandy, Brittany and north-eastern Italy (Hollstein et al, 1991;
Audrezet et al, 1993; Esteve et al, 1993; Li et al, 2000; Robert 
et al, 2000; Shirvani et al, 2000). In these areas, many mutations
occur at A:T basepairs (45% of all mutations), a type of mutation
which is infrequent in other cancers and in SCCE from other parts
of the world. This type of mutation is consistent with DNA
damage inflicted by acetaldehyde, the first metabolite of ethanol
(Tudek et al, 1999). Interestingly, several studies have shown an
association between a functional polymorphism in aldehyde dehy-
drogenase 2 (ALDH2) and the risk of SCCE, suggesting that
acetaldehyde may represent an important oesophageal carcinogen
(Yang et al, 1999; Aggarwal et al, 2000). 
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Summary In Europe, high incidence rates of oesophageal squamous cell carcinoma (SCCE) are observed in western France (Normandy and
Brittany) and in north-eastern Italy. Analysis of TP53 mutations in tumours from these regions has shown a high prevalence of mutations at
A:T basepairs that may result from DNA damage caused by specific mutagens. However, the spectrum of TP53 mutations in regions of low
incidence is unknown. We report here TP53 mutation analysis in 33 SCCE collected in Lyon, an area of low incidence. These tumours were
also examined for MDM2 and P63 amplification, and for expression of p16INK4a/CDKN2a, cyclin E, p27Kipl and Cox2. TP53 mutations were
detected in 36% of the cases (12/33). In contrast with regions of high incidence, the mutation spectrum did not show a high prevalence of
mutations at A:T base pairs. P63 was amplified in 5/32 cases tested (15.5%). No amplification of MDM2 was found. Expression studies
revealed frequent loss of p16INK4a/CDKN2a (46%) and p27Kipl (25%) expression, and frequent overexpression of Cyclin E (70%) and Cox2 (42%).
Overall, these results indicate that in Europe, SCCE from areas of high and low incidence present a similar pattern of molecular alterations
but differ by the type of TP53 mutations. © 2001 Cancer Research Campaign http://www.bjcancer.com
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cohort of 33 SCCE patients from a low-incidence area of south-
eastern France (Lyon, Rhône-Alpes region). In this region the
reported incidence of SCCE (ASR) is 10/100 000/year in men and
1/100 000/ in women (Parkin et al, 1997). We have also analysed
amplification in genes suspected to play a role in the pathogenesis
of SCCE, P63 and MDM2, P63 encodes a homologue of p53 that
plays an essential role in the development of squamous epithelial.
Mice lacking this gene die at birth from multiple defects due to
improper skin formation (Yang et al, 1999). This gene is often
amplified in primary human squamous carcinomas of the lung and
the head and neck (Hibi et al, 2000; Yamaguchi et al, 2000).
MDM2 encodes a protein that binds to p53, inhibits its transcrip-
tional activity and induces its degradation. Several studies have
shown amplification of MDM2 in a proportion of SCCE (14%)
(Momand et al, 1998), suggesting that this phenomenon may
represent a functional alternative to inactivation of TP53 by muta-
tion. We have also analysed by immunohistochemistry the expres-
sion of the cell cycle regulatory proteins p16INK4a/CDKN2a, cyclin E
and p27Kipl, as well as of cyclo-oxygenase 2 (Cox2). We report that
the prevalence and pattern of TP53 mutations in this cohort differ
from the ones reported in cohorts from high incidence areas of
Europe. In addition, we describe for the first time that P63 is
amplified in a significant proportion of SCCE (15.3%). 
MATERIALS AND METHODS 
Patients and tumours 
Tumour tissues were collected from patients recruited at Hôpital
E. Herriot (Lyon, France). All patients were residents in the Lyon
area. The criteria for inclusion in the study were (1) presence of 
a primary SCCE, (2) no primary treatment, (3) signature of an
informed consent form. Tissue samples were biopsies collected
during endoscopy or samples from surgical pieces. All samples
were evaluated by histology. Tumour staging was performed
according to the TNM classification (TNM atlas, 4th edition
1997). For biopsies, the stage of the tumour was evaluated by
ultrasonography. Clinical charts were reviewed to collect informa-
tion on the patient’s past medical history, tobacco and alcohol
consumption, and follow-up after diagnosis and treatment. The
tissue and data collection protocols were approved by local and
institutional ethical committees. 
DNA extraction and TP53 mutation detection 
DNA was isolated from microdissected tissue fixed in 10%
buffered formalin and embedded in paraffin. After re-hydration,
areas of interest were scraped and transferred to extraction buffer
(50 µ l, Tris-HCl 10 mM pH 9, Proteinase K 0.1 µ gm l –1, Nonidet
P40 0.1%) and incubated for 3 days at 56˚C with proteinase K.
TP53 exons 5 to 8 were analysed by temporal temperature gradient
electrophoresis (TTGE) using the DCode system (BioRad,
Richmond, CA) as described previously (Tanière et al, 2000a).
Samples that showed additional and/or abnormal bands were re-
amplified from genomic DNA and a second TTGE was performed
as a confirmation. Bands corresponding to mutant alleles were cut
from the second TTGE, re-amplified using the same primers and
analysed by direct sequencing after asymmetric PCR as previously
described (Barnas et al, 1997; Tanière et al, 2000a). 
Immunohistochemistry 
Deparaffinized tissue sections were labelled using standard proto-
cols, after antigen unmasking procedures (3 × 5 minutes in a
microwave oven for slides labelled with anti-Cox2, cyclinE and
p27Kipl antibodies, and 10 minutes in a pressure cooker for
labelling with anti-mdm2). The following primary antibodies 
were used: CM1 (purified rabbit IgG anti-human p53, 1/500,
Novocastra Laboratories Ltd, Newcastle, UK), MDM2 (Ab-1)
(monoclonal antibody, clone IF2, 1/100, Calbiochem, San Diego,
CA), p16INK4a/CDKN2a (monoclonal antibody, clone F12, 1/1600,
Santa Cruz Biotechnology, Santa Cruz, CA), Cox2 (polyclonal
antibody, clone C-20, 1/1000, Santacruz Biotechnology, Santa
Cruz, CA), cyclin E (monoclonal antibody, clone HE-12, 1/2000,
Santa Cruz Biotechnology, Santa Cruz, CA), p27Kipl (monoclonal
antibody, clone 1B4, 1/1000, Novocastra Laboratories Ltd,
Newcastle). The specificity of the antibodies was checked by
Western blot using extracts of oesophageal cancer cell lines TE1,
TE6 and TE11 (Barnas et al, 1997; Pluquet et al, unpublished
data). Negative immunohistochemistry controls were performed
by omission of the primary antibody. Fixed antibodies were
detected using either anti-mouse or anti-rabbit biotinylated IgG
(1/200 Vectasin Elite-ABC kit, Vector Laboratories Inc.) followed
by streptavidin-peroxidase (1/50, 30 minutes at 37˚C) and
diaminobenzidine-based detection (Vector Laboratories, Inc.). For
Cox2 and cyclinE, tumours were considered as positive when 
at least 10% of tumour cells were labelled. For p27Kipl and
p16INK4a/CDKN2a, tumours were considered as negative when less
than 10% of the tumour cells were stained. 
Amplification of MDM2 and P63
Amplifications were detected by differential PCR using the
dopamine D2 receptor gene (DRD2) as a reference (Biernat et al,
1997). Genomic DNA was amplified in 25 µ l of a reaction mixture
containing sense and anti-sense primers for either MDM2 or P63
(20 pmol) and DRD2 (10 pmol), 200 µ M of each dNTP, 1 × ampli-
fication buffer, 2.5 mM of MgCl2, and 0.5 µ l (2.5 units) of Taq
Platinum DNA polymerase (Life Technologies). PCR conditions
were: 2 minutes at 94˚C, followed by 27 cycles at 95˚C for 45
seconds, 55˚C (MDM2) or 53˚C (P63) for 45 seconds and 72˚C for
1 minute with a final extension at 72˚C for 5 minutes. The primers
used in MDM2 differential PCR were those described in Biernat 
et al (1997). For P63 differential PCR, we defined the following
primers in P63 exon 7 (Genbank access number AF116762): 
5′ -CCT ATT TGA ATT ACA TGA TGT GGA T-3′ (sense) and 
5′ -CAA ACT CTG AAC CCT GTT GTA GA-3′ (anti-sense). A
fragment of DRD2 with matched amplification conditions was
defined with the following primers: 5′ -GTT TGC TCA ATT TGT
CCT ACC AG-3′ (sense) and 5′ -GGG ATT TTA AGG TTT ACG
GCT AA-3′ (anti-sense). For both differential PCR assays, prod-
ucts were electrophoresed on 3% agarose gels stained with
ethidium bromide and analysed by scanning densitometry (BioRad
GS-670, Hercules, CA). Each analysis was repeated at least 3
times in independent PCR experiments. A ratio of 2.5 (average of
at least three measurements) or above between the specific MDM2
or  P63 bands and the DRD2 reference band was regarded as
indicative of gene amplification. 
722 P Tanière et al
British Journal of Cancer (2001) 85(5), 721–726 © 2001 Cancer Research Campaign
BJOC 01-1990 721-726  20/8/01  3:52 pm  Page 722RESULTS 
Clinical and individual characteristics of the patients 
The mean age of the 33 patients included in the study was 61 years
(range 45–80 years). 29 were men and 4 were women. 5 patients
had developed another tumour several years before the occurrence
of SCCE: patient 2 (adenocarcinoma of the colon), patient 
4 (malignant T-cell lymphoma), patient 19 (squamous cell carci-
noma of the lung) and patients 14 and 23 (squamous cell 
carcinoma of the head and neck). 2 patients received a liver
(patient 1) or renal (patient 9) transplant several years before
SCCE. Patient 25 was surgically treated during childhood for
congenital mega-oesophagus. 
Reliable information on tobacco consumption was available for
23 patients. 22 (96%) were regular smokers (more than 5 pack-
years). Information on alcohol intake was available for 21 patients.
17 of them were considered as heavy drinkers (daily alcohol intake
over 80 g). All of these 17 patients were heavy smokers. 
The pathological staging was available for all resected tumours.
For patients for whom only a biopsy was available, the staging was
performed by ultrasonoendoscopy. According to the TNM classifi-
cation, 2 tumours were stage T1, 4 were stage T2, 21 were stage
T3 and 3 were stage T4. 19 of the T3 and all T4 tumours showed
lymph node involvement (N1). 2 patients (14 and 26) presented 2
distinct infiltrative lesions, and 3 patients (15 and 24) showed
multiple dysplastic areas distant from the tumour. 
TP53 mutations 
A total of 13 TP53 mutations were detected in 12/33 (36%) of the
patients. These mutations are listed in Table 1. They are distributed
over the exons of the DNA-binding domain (3 in exon 5, 3 in exon
6, 3 in exon 7 and 4 in exon 8). One tumour (12) contained 2
mutations. Of the 11 missense mutations, 3 were transversions and
8 were transitions, 4 of which were C to T occurring within
dipyrimidine repeats. 
3 mutations gave a null-p53 phenotype (patient 1: nonsense
mutation at codon 132; patients 2 and 3: 2-base pair deletion and
frameshift at codons 186 and 209, respectively). These 3 tumours
were negative for p53 immunostaining. Among tumours with
missense mutations, 7/9 were positive for p53 immunostaining.
Interestingly, tumours 10 and 11 showed opposite staining
patterns, although they harboured the same mutation. It is also
important to note that 3 tumours without mutations in exons 5–8
were found positive for p53 immunostaining (patients 28, 29 and
31). These tumours may contain a mutation outside the regions
analysed. 
Amplification of MDM2 and of P63
Amplification of P63 was observed in 5 of the 32 cases tested
(15.5%), as detected by P63/DRD2 gene ratios of 2.5 or above
(Figure 1). 2 of these tumours also harboured a TP53 mutation. 
None of the 27 tumours tested showed MDM2 gene amplifica-
tion (Table 2). However, many tumours showed mdm2 protein
expression detected by immunohistochemistry in a variable
proportion of tumour cells. It is important to note that mdm2 is
constitutively expressed in cells of the parabasal layers of normal
oesophageal epithelium. 
Immunohistochemical detection of p16INK4a/CDKN2a, Cox2,
cyclin E and p27Kip1
Figure 2 shows typical expression patterns for p16INK4a/CDKN2a,
Cox2, cyclin E and p27Kip1. P16INK4a/CDKN2a is constitutively
expressed in the basal cell layer of normal oesophageal epithelium.
P16INK4a/CDKN2a was detectable in tumour cells in 15/28 (54%) cases
tested, but lost in the remaining 13 cases (46%). 5 of these
p16INK4a/CDKN2a negative cases also contained a TP53 mutation.
Cox2 expression was not detectable in normal oesophageal epithe-
lium. 10/24 (42%) tumours tested were found positive for Cox2
expression (10–80% of cells stained). There was a trend of an
association between positivity for Cox2 and advanced tumour
stage, since only 1/7 T1, T2 and T3N0 tumours showed Cox2
expression (in 10–20% of the cells), compared with 9/17 T3N1
and T4 tumours (in at least 20% of the cells) (P = 0.069) (based on
the 24 samples for which information on stage and Cox2
immunostaining were available, see Table 2). Cyclin E was incon-
stantly detectable in normal oesophageal epithelium, but was
found in at least 10% of tumour cells in 16/23 (70%) cases tested,
with no association with the tumour stage. Expression of p27Kip1
was detectable in the parabasal layers of the non-involved epithe-
lium adjacent to the tumour in all the cases. The protein was also
Alterations of TP53 and P63 in oesophageal cancers 723
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Table 1 TP53 mutations in SCCE from a low incidence area of France
(Lyon)(a)
Case Codon Base change Amino-acid change 
1 132 AAG→ TAG Tyr-Stop 
2 186 2 bp deletion 
3 209 2 bp deletion 
4 220 TAT→ TGT Tyr-Cys 
5 245 GGC→ AGC Gly-Ser 
6 245 GGC→ TGC Gly-Cys 
7 248 CGG→ CAG Arg-Gln 
8 272 GTG→ ATG Val-Met 
9 272 GTG→ ATG Val-Met 
10 273 CGT→ TGT Arg-Cys 
11 273 CGT→ TGT Arg-Cys 
12 135 TGC→ TGT Cys-Phe 
13 218 GTG→ GAG Val-Glu 
aFurther information on sex, age and past medical history are available on:
http://www.iarc.fr/p53 
MW marker
Blank
23 45
Samples
− p63 (166 bp)
− DRD2 (102 bp)
Figure 1 Amplification of p63 as detected by differential PCR. Tumour
samples were analysed by differential PCR for P63 gene amplification. A
fragment of the DRD2 gene was used as an internal standard. PCR products
were analysed on a 3% agarose gel, stained with ethidium bromide and
photographed; films were analysed by densitometry (see Materials and
methods). A threshold of 2.5 was considered indicative of P63 amplification.
The intensity of the 2 bands was similar in DNA samples from normal tissue
(lane 2). In tumours (lanes 3–5), the intensity of P63 band was at least 2.5
stronger than the DRD2 band in samples 3 and 4, indicative of gene
amplification. In contrast, sample 5 did not show amplification 
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tion, but lost in the remaining cases (25%). 
DISCUSSION 
Our results showed that TP53 mutations in the low-incidence area
of Lyon were relatively less frequent (36%) than in high-incidence
areas of Europe, where mutation prevalence ranges from 56% (in
northern Italy (Esteve et al, 1993) ) to 80% (in Normandy/Brittany
(Audrezet et al, 1993; Robert et al, 2000) ). This rather low preva-
lence of mutations was not compensated by a high prevalence of
MDM2 amplification. 
Despite its limited size, the present case series also showed a
number of other interesting molecular characteristics. In particular,
the TP53-related gene P63 was amplified in 5/32 cases (15.5%).
This gene has been found to be frequently amplified in squamous
cell carcinomas of the lung and of head and neck and is also
known as AIS (Amplified In Squamous Carcinomas) (Hibi et al,
2000). The P63 gene encodes a transcription factor that regulates
genes that overlap with those controlled by TP53. In contrast with
TP53, P63 shows a specific developmental pattern of expression
and appears to be required for the normal differentiation of squa-
mous epithelia (Yang et al, 1999). It is interesting to note that P63
can be expressed in several isoforms (splicing variants), some of
them lacking the N-terminal domain, transactivation domain.
These N-terminal variants may thus behave as competitors for the
full-length, active form (Yang et al, 1998). In keratinocytes,
expression of such forms of P63 is restricted to cells with high
proliferative potential (Parsa et al, 1999). Such an inhibition of the
antiproliferative effects of full-length P63 may account for the
oncogenic role of amplified P63/AIS. However, our data do not
support the hypothesis that P63 amplification is an alternative
pathway for inactivation of TP53, as amplification was equally
detected in tumours with wild-type (3/5) or mutant (2/5) TP53. 
Another interesting characteristic of the series of SCCE
analysed here is the association of Cox2 overexpression with
advanced tumour stage. Such a positive association has been
reported for many epithelial tumours, including head and neck
cancers, colon cancers and both squamous cell and adenocarci-
nomas of the oesophagus (Ratnasinghe et al, 1999; Zimmermann
et al, 1999). It is important to note that, in this study, we have
considered staining in 10% of tumour cells as a threshold for posi-
tivity, a criterion more stringent than in several recent studies.
Cox2 is known to enhance the synthesis of prostaglandin E2, to
increase cell proliferation, angiogenesis and immune suppression
and to facilitate inhibition of apoptosis. It is not known whether
overexpression of Cox2 contributes to carcinogenesis or rather
accompanies tumour progression as a marker of cellular stress. 
Our results on p16INK4a/CDKN2a and p27Kip1 expression confirm
recent data showing that these 2 negative regulators of cell cycle
are down-regulated in a variable proportion of SCCE (20–40%)
(Itami et al, 1999; Ohashi et al, 1999; Shamma et al, 2000). In
724 P Tanière et al
British Journal of Cancer (2001) 85(5), 721–726 © 2001 Cancer Research Campaign
Table 2 Molecular alterations in SCCE patients from a low incidence area of France (Lyon) 
Case TNM Grade p53 IHC TP53 Mutation Mdm2 IHC MDM2 amplification P63 amplification 
1 T2N0 WD 0 + > 50 ––  
2 T3N1 MD 0 + > 50 ––  
3* NA PD 0 + ND ND – 
4 T1N0 WD > 50 + > 50 ND – 
5 T2N0 MD 0 + 10–20 ––  
6* T4N1 WD > 50 + ND ––  
7 T3N1 PD 10–20 + 10–20 ––  
8* T3N1 WD 10–20 + ND – + 
9* T3N1 WD > 50 + 10–20 ––  
10 T3N1 WD 0 + 10–20 – + 
11 T3N1 WD > 50 + > 50 ––  
12* T3N1 MD 10–20 + 10–20 ––  
13 T3N1 WD 0 – 10–20 ––  
14 T3N1 MD 0 – 20–50 ––  
15* T4N1 PD 0 – ND + – 
16* T3N1 MD 0 – ND ND – 
17 T3N1 PD 0 – 0 – + 
18* T3N1 WD 0 – >5 0 – + 
19 T2N1 WD 0 – 0 – + 
20* T3N1 MD 0 – >5 0 – ND 
21 T4N1 MD 0 – 10–20 ––  
22* NA MD 0 – 0 ––  
23 NA MD 0 – >5 0 N D – 
24 T3N0 WD 0 – >5 0 ––  
25 T3N0 WD 0 – 10–20 ––  
26 T3N1 WD 0 – 10–20 ––  
27 T2N0 WD 0 – 20–50 ––  
28* T3N1 WD > 50 – 20–50 ––  
29* T3N1 MD > 50 – 10–20 ––   
30* NA WD – ND ––  
31* T3N1 MD 10–20 – 0 ––  
32* T3N1 PD 0 – 0 ––  
33 T3N1 WD 0 – ND ––  
*:biopsy; WD, MD, PD: well-, moderately-, poorly-differentiated; NA: not available; IHC: immunohistochemistry (percentage of stained cells in the tumour tissue);
ND: not done (no more material available). 
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levels of Cyclin E. High expression of Cyclin E has been reported
in the majority of oesophageal cancer cell lines (Fujii et al, 1998)
and in about 30% of primary SCCE (Anayama et al, 1998).
Overexpression of Cyclin E has also been observed in preneo-
plastic lesions and in papillomas in nitrosomethylbenzylamine-
induced oesophageal tumorigenesis in rats (Wang et al, 1996).
Overall, these data support the observation that molecules involved
in the control of cell cycle progression from G1 to S phase are
often altered in SCCE. In gastric cancers, it has been shown that
high levels of Cyclin E expression together with low levels of p21
and p27Kip1, correlate with deep invasion. Such a correlation is not
seen in our series of cases, as elevated Cyclin E expression was
detected in 5/6 T1, T2 and T3N0 tumours, compared to 10/15
T3N1 and T4 tumours. The data available to date do not allow us
to evaluate whether there are significant variations in the preva-
lence of these alterations between different geographic areas. 
In many cancers, the pattern of TP53 mutations is informative of
the mutagens involved as causal agents. In Figure 3, we have
grouped the data reported here with those of the IARC TP53 muta-
tion database. Compared with high-incidence areas, tumours from
low-incidence areas show a significantly lower prevalence of tran-
sitions and transversions at A:T basepairs, a type of mutation
which has been frequently detected in cancers of the oesophagus
and of the head and neck, and which may result from the muta-
genic action of metabolites of ethanol, such as acetaldehyde. In
both high- and low-incidence areas, the main etiological agents
implicated so far are the combined consumption of alcohol and
tobacco (Launoy et al, 1997, 2000). However, the relative rarity of
mutations at A:T basepairs in patients from low-incidence areas,
most of whom were heavy drinkers, gives support to the idea that
additional factors act as modifiers of the effect of alcohol. Among
them, the type of oral microflora and the polymorphism of alde-
hyde dehydrogenase 2 (ALDH2) have been shown to be important.
Indeed, high levels of acetaldehyde in the upper digestive tract are
thought to derive from microbial oxidation of ethanol by the oral
Alterations of TP53 and P63 in oesophageal cancers 725
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Figure 2 Immunohistochemical detection of cyclin E (A), Cox2 (B), p27Kipl (C) and p16INK4a/CDKN2a (D) in SCCE. (A) More than 50% of the tumour cells were
stained in the nucleus with anti-Cyclin E antibody. (B) 20–50% of the tumour cells expressed Cox2 in the cytoplasm. (C) Only 10–20% of the tumour cells
expressed the p27Kip1 protein. Lymphocytes and plasma cells were strongly stained and used as a positive control. (D) p16INK4a/CDKN2a expression was lost in
tumour cells. In contrast, the non-dysplastic squamous epithelium of the oesophagus showed a focal p16INK4a/CDKN2a expression in the basal cell layers (insert).
Scale: A, B and D (inset): 1 cm = 100 µ M; C and D: 1 cm = 500 µ M 
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Figure 3 Comparison between mutation patterns of primary SCCE from
high- and low-incidence areas from Europe. Data reported in this article and
in the published literature were used (source: IARC TP53 mutation database
at http://www.iarc.fr/p53; version R5, June 2001) were used. High-incidence
areas: Normandy/Brittany and northern Italy (77 mutations). Low-incidence
areas: Lyon (France), Paris (France) and Lausanne (Switzerland) (39
mutations) 
BJOC 01-1990 721-726  20/8/01  3:52 pm  Page 725microflora. The composition and quantities of the oral microflora
may vary from one area to another and therefore
influence the actual levels of acetaldehyde that can damage the
oesophageal mucosa (Muto et al, 2000b). Furthermore, it is impor-
tant to note that a polymorphism in ALDH2 has been found to be
associated with a higher risk of head and neck and of oesophageal
cancers (Muto et al, 2000a). Whether these factors contribute to
explain the variations in incidence of SCCE in Western Europe
awaits further evaluation. It will also be important to evaluate
whether the pattern of TP53 mutations in other cancers related 
to alcohol intoxication, such as oral cancer and hepatocellular
carcinomas, also vary from one geographic area to another. 
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